Selank is a synthetic heptapeptide developed in Russia in the 1990s as a stabilized analog of tuftsin, designed primarily to reduce anxiety without the sedation, dependence, or withdrawal linked to benzodiazepines. The evidence behind that promise comes almost entirely from small Russian trials and animal models, and Selank has not been approved by the FDA or replicated in large Western randomized controlled trials, so its efficacy and long-term safety remain unestablished by the standards applied to registered medicines. In the United States it is sold only as a research chemical labeled not for human consumption, which places quality, dosing accuracy, and legal risk on the buyer.
Selank is a Russian-developed heptapeptide analog of tuftsin whose anxiolytic reputation rests on small Russian trials and animal studies, with no FDA approval and no large Western replication to establish its efficacy or long-term safety.
Selank's structure is a seven-amino-acid chain, threonine-lysine-proline-arginine-proline-glycine-proline, whose first four residues reproduce tuftsin, an endogenous tetrapeptide cleaved from the heavy chain of immunoglobulin G. Native tuftsin is degraded by peptidases within minutes, so researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences appended a proline-glycine-proline tail that resists enzymatic cleavage and extends the molecule's duration of action while keeping its neuroactive character.
Selank is a synthetic heptapeptide built from the tuftsin tetrapeptide plus a proline-glycine-proline tail that resists peptidase degradation, extending the parent molecule's half-life while preserving its neuroactive profile.
The mechanism attributed to Selank is multi-pronged rather than tied to a single receptor. Research links its calming effect mainly to modulation of the GABAergic and serotonergic systems and to a documented shift in monoamine balance, alongside a frequently cited effect on enkephalins, where Selank appears to slow the enzymes that degrade these endogenous opioid peptides. Much of this pathway work rests on animal and cell models rather than confirmed human data.
Selank's reported activity spans GABAergic and serotonergic modulation, enkephalinase inhibition, and increased hippocampal BDNF expression, though the BDNF and immune findings derive largely from rodent and cell-model work rather than human trials.
Anxiety reduction is the effect most studied and most central to Selank's identity, with Russian trials in generalized anxiety disorder reporting reductions comparable in some measures to standard anxiolytics but without pronounced sedation. Beyond that, the reported benefits fall on visibly different evidence tiers, and marketing material routinely overstates what the underlying studies actually demonstrated.
Selank's anxiolytic effect is supported by small human trials, whereas its nootropic, neuroplastic, and immune-modulating claims rest largely on rodent and cell-model data that has not been confirmed in humans.
The clinical literature on Selank is real but thin, and it is overwhelmingly Russian. Human studies have been run mainly at Russian research institutes with small sample sizes and designs that would not meet the scale or rigor of a modern registration trial, and none has been independently replicated at scale abroad.
The human evidence for Selank consists of small, short, largely unreplicated Russian trials, and the compound has not been approved by the FDA, the EMA, or comparable Western regulators.
Selank has no approved therapeutic status in the United States: the FDA has not evaluated or approved it for any medical use, and it is neither a prescription nor a compounding-friendly product. It is instead sold as a research chemical explicitly labeled not for human consumption, a designation that shifts the legal and safety burden onto the buyer rather than signaling quality. The regulatory picture also changes by jurisdiction and by who is using the compound.
Selank has no FDA-approved medical use in the United States and is sold only as a research chemical labeled not for human consumption, a designation that transfers all legal and safety liability to the buyer.
Because Selank is a peptide, it is used almost exclusively by routes that bypass the digestive tract, where stomach acid and gut enzymes would degrade it before it reached circulation. The intranasal route dominates the Russian clinical work, while subcutaneous injection is common in gray-market self-administration, and reported effects build over a course rather than acting like a single sedating dose.
Selank has been administered in Russian studies as an intranasal solution given in divided daily doses over courses of roughly one to several weeks, since as a peptide it is degraded in the digestive tract and its effects accumulate over repeated administration rather than a single dose.
In the trials run so far, Selank has been reported as generally well tolerated, with few and mild side effects and without the sedation, dependence, or withdrawal seen with benzodiazepines. The important qualification is that this reassurance rests on small, short-duration studies, so the absence of reported harm is partly an absence of investigation rather than proof of safety.
Selank's reported safety rests on small, short-duration trials that leave its long-term effects, use in vulnerable populations, and drug interactions unstudied, and the gray-market supply adds documented risks of contamination, mislabeling, and dosing error that are separate from the molecule itself.
Selank is frequently paired with Semax because both are Russian-developed regulatory peptides derived from short endogenous sequences, but they aim at different targets: Selank is primarily anxiolytic, while Semax, an ACTH fragment analog, is framed as a nootropic and neuroprotective agent. Against approved anxiety treatments the contrast is sharper, and the decisive difference is evidence and accountability rather than the claimed effect.
| Treatment | Onset & evidence | Dependence / oversight |
|---|---|---|
| Benzodiazepines | Fast, well-characterized, FDA-approved | Sedation, tolerance, dependence, withdrawal |
| SSRIs / SNRIs | Slow onset, large evidence base, FDA-approved | Low dependence, prescribed with medical oversight |
| Selank | Claimed rapid onset, limited Russian data, not approved | No dependence reported, no regulatory oversight |
Benzodiazepines and SSRIs are FDA-approved anxiety treatments backed by large evidence bases and medical oversight, whereas Selank's claimed advantage of relief without dependence rests on limited Russian data and an unregulated supply chain, making its choice a trade of proven, accountable treatment for an unproven one.
Because Selank has no approved pharmaceutical supply, nearly all of it reaches users through research-chemical vendors, and product quality varies widely with no external guarantee. Independent testing across the research-peptide sector has repeatedly found incorrect peptide content, low purity, wrong or degraded compounds, and bacterial or endotoxin contamination, which makes the sourcing question inseparable from the safety question.
With no approved pharmaceutical supply, Selank reaches buyers through research-chemical vendors where independent testing has repeatedly documented incorrect content, low purity, and contamination, and no enforced manufacturing standard, batch traceability, or recourse exists to protect the purchaser.
Educational use only. This article describes what the published scientific and clinical literature reports about Selank. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
